Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120649 | 0.91 | CDK2 (0.58) | GSK3BCDK2MAPK1SMN1; SMN2HTT | |
| SCHEMBL13288977 | 0.90 | CDK2 (0.47) | GSK3BCDK2SMN1; SMN2HTTMEN1 | |
| SCHEMBL13288964 | 0.88 | ALDH1A1 (0.48) | GSK3BCDK2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL12954278 | 0.88 | CDK2 (0.52) | GSK3BCDK2RAB9AMEN1KMT2A | |
| SCHEMBL13289431 | 0.88 | CDK2 (0.49) | GSK3BCDK2RAB9AMEN1KMT2A | |
| SCHEMBL13288973 | 0.87 | CDK2 (0.48) | GSK3BCDK2ALDH1A1 | |
| SCHEMBL14607112 | 0.85 | CDK2 (0.46) | GSK3BCDK2RAB9AALDH1A1 | |
| SCHEMBL13288974 | 0.85 | CDK2 (0.52) | GSK3BCDK2RAB9AMEN1KMT2A | |
| SCHEMBL13289375 | 0.85 | CDK2 (0.54) | GSK3BCDK2RAB9AMEN1KMT2A | |
| SCHEMBL13289432 | 0.84 | CDK2 (0.47) | GSK3BCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |